Acrivon Therapeutics, Inc./$ACRV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Ticker
$ACRV
Sector
Primary listing
Employees
75
Headquarters
Website
ACRV Metrics
BasicAdvanced
$61M
-
-$2.02
1.80
-
Price and volume
Market cap
$61M
Beta
1.8
52-week high
$3.56
52-week low
$1.05
Average daily volume
831K
Financial strength
Current ratio
7.689
Quick ratio
7.57
Long term debt to equity
1.366
Total debt to equity
2.408
Profitability
EBITDA (TTM)
-82.758
Management effectiveness
Return on assets (TTM)
-32.22%
Return on equity (TTM)
-53.86%
Valuation
Price to book
0.44
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-0.925
Free cash flow yield (TTM)
-108.06%
Free cash flow per share (TTM)
-1.697
Growth
Earnings per share change (TTM)
-15.14%
3-year earnings per share growth (CAGR)
-35.56%
ACRV News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Acrivon Therapeutics, Inc. stock?
Acrivon Therapeutics, Inc. (ACRV) has a market cap of $61M as of April 07, 2026.
What is the P/E ratio for Acrivon Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Acrivon Therapeutics, Inc. (ACRV) stock is 0 as of April 07, 2026.
Does Acrivon Therapeutics, Inc. stock pay dividends?
No, Acrivon Therapeutics, Inc. (ACRV) stock does not pay dividends to its shareholders as of April 07, 2026.
When is the next Acrivon Therapeutics, Inc. dividend payment date?
Acrivon Therapeutics, Inc. (ACRV) stock does not pay dividends to its shareholders.
What is the beta indicator for Acrivon Therapeutics, Inc.?
Acrivon Therapeutics, Inc. (ACRV) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.